Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-91

It's a good idea to go back and listen to the presentation from this arvo again..CG has highlighted some very important points in the trial..

Again it's a positive and a negative for everyone, but I am guessing in absence of a Partner to finance or having a good amount of $$, this is the best option ..

$$ cant be organized is the issue that starts with MDs capabilities and contacts but coming back to the real world we do not have the required $$ but with this plan we are moving to the clinics asap for a very important trial.

I see a good opportunity for accelerated approval if we have robust positive data...Not just in Europe but also in the USA...talks about harmonizing the approval trial is still in the loop..

Looks like someone is directing ANP on what to do...


IMO DYOR...